Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study. Pdf primary prevention of cardiovascular disease with. Stroke prediction and stroke prevention with atorvastatin in. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of preexisting vascular disease and who had only. We aimed to identify adultonset autoimmune diabetes in patients with established type 2 diabetes participating in the collaborative atorvastatin diabetes study cards to characterize their phenotype and clinical outcome. We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 6575 years at randomization with 1,709 younger patients in the collaborative atorvastatin diabetes study cards. Effects of atorvastatin on kidney outcomes and cardiovascular. This and the adherence rate were from the collaborative atorvastatin diabetes study cards, a randomised controlled trial with a 3. The trial was stopped 2 years earlier than planned because of significant benefit at the second interim analysis. An overview of cards collaborative atorvastatin diabetes study. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of preexisting vascular disease and who had only average or below average cholesterol levels. Dec 01, 2007 we previously reported that allocation to atorvastatin 10 mg daily to 2838 patients with type 2 diabetes and no prior cardiovascular disease was associated with a 48% reduction in stroke risk in the collaborative atorvastatin diabetes study cards in the context of an average reduction in ldl cholesterol of 1. It received ethical approval both centrally and at each participating institution and each patient gave written informed consent. Rapid emergence of effect of atorvastatin on cardiovascular.
The collaborative atorvastatin diabetes study cards randomised patients to either atorvastatin 10mg per day or to placebo. Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains. Atorvastatin reduced cv events even in low ldl dm patients. Dec 19, 2019 in the collaborative atorvastatin diabetes study cards, the effect of atorvastatin calcium on cardiovascular disease cvd endpoints was assessed in 2838 subjects 94% white, 68% male, ages 40 to 75 with type 2 diabetes based on who criteria, without prior history of cardiovascular disease and with ldl. Subjects and methods a total of 2,838 patients, who were aged 40 to 75 years and had type 2 diabetes without a documented history of cardiovascular disease and without elevated ldlcholesterol, were recruited from 32 centres in the uk and ireland and randomly allocated to atorvastatin. Mar 01, 2009 the collaborative atorvastatin diabetes study cards was a doubleblind, randomized, placebocontrolled, multicenter trial of atorvastatin 10 mgday for the primary prevention of cvd in type 2 diabetes.
We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 6575 years. Atorvastatin reduced major cardiovascular disease events. Costeffectiveness of primary prevention of cardiovascular disease. The primary objective is to investigate whether treatment with the hydroxymethylglutaryl coenzyme a reductase inhibitor. Collaborative atorvastatin diabetes study cards diabetes care. The collaborative atorvastatin diabetes study cards. In this trial, known as cards the collaborative atorvastatin diabetes study, atorvastatin had a similar tolerability profile to that of placebo. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study cards. Collaborative atorvastatin diabetes study cards or card. Collaborative atorvastatin diabetes study american college.
Cost effectiveness of atorvastatin in patients with type 2. Department of medicine, royal free and university college medical. Safety of atorvastatin in the collaborative atorvastatin diabetes study cards the safety and efficacy of sta the safety and efficacy of statins for cvd prevention is well established, yet some physicians have concerns about the longterm safety of this class. Collaborative atorvastatin diabetes study cards and fol lowed for 3. In the collaborative atorvastatin diabetes study cards, the effect of atorvastatin calcium on cardiovascular disease cvd endpoints was assessed in 2838 subjects 94% white, 68% male, ages 40 to 75 with type 2 diabetes based on who criteria, without prior history of cardiovascular disease and with ldl.
Therefore, the first aim of this article is to report the effect of atorvastatin on albuminuria and estimated gfr gfr in one of the largest randomized trials n 2,838 of statin therapy in people with diabetes. Atorvastatin reduced major cardiovascular disease events in. Methods the collaborative atorvastatin diabetes study cards is a multicentre, randomized, placebo. Objective rates of cardiovascular disease are highest in the elderly. An overview of cards collaborative atorvastatin diabetes study primary prevention of cardiovascular disease with atorvastatin in type 2. Costeffectiveness of primary prevention of cardiovascular. The safety and tolerability of atorvastatin 10 mg in the. The goal of the collaborative atorvastatin diabetes study cards trial was to determine the effectiveness of the lipidlowering agent atorvastatin in reducing cardiovascular events and death among diabetic patients with at least one heart disease risk factor, but without elevated cholesterol.
Apolipoproteins, cardiovascular risk and statin response in. Aug 21, 2004 the aim of the collaborative atorvastatin diabetes study cards was to assess the effectiveness of 10 mg of atorvastatin daily versus placebo in the primary prevention of cardiovascular disease in patients with type 2 diabetes. Patients with type 2 diabetes and no prior cvd n 2,838. Thus, atorvastatin has a potential role in the primary prevention of cardiovascular events in diabetic patients at risk of chd, irrespective of pretreatment ldlcholesterol levels. The safety and tolerability of atorvastatin 10 mg in the collaborative. Pdf there are few data on the role of lipid lowering in the primary prevention of coronary heart disease chd in diabetic patients. Collaborative atorvastatin diabetes study listed as cards. This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. In 2,627 participants without known vascular disease in the collaborative atorvastatin diabetes study, apob, apoai, ldlcholesterol ldlc and hdl. Oct 30, 2008 controversy surrounds whether the ratio of apolipoprotein b apob to apolipoprotein ai apoai is the best lipoprotein discriminator of chd risk in nondiabetic populations, but the issue has never been investigated in type 2 diabetes. The collaborative atorvastatin diabetes study cards is the first randomized controlled trial that assessed the effectiveness and safety of using atorvastatin in patients with type 2 diabetes with no prior history of cardiovascular disease. Among these studies 1422 are the heart protection study hps, 14 the collaborative atorvastatin diabetes study ca r ds, 15 the angloscandinavian cardiac outcomes lipid lowering arm ascotlla, 16 the antihypertensive and lipid lowering treatment to prevent heart. Last year, these investigators reported a 37% reduction in the primary outcome, a composite of acute coronary. The study received ethical approval both centrally and at each participating institution, and each patient gave written informed consent.
Collaborative atorvastatin diabetes study american. An analysis from the collaborative atorvastatin diabetes study cards author links open overlay panel helen m. We previously reported that allocation to atorvastatin 10 mg daily to 2838 patients with type 2 diabetes and no prior cardiovascular disease was associated with a 48% reduction in stroke risk in the collaborative atorvastatin diabetes study cards in the context of an average reduction in ldl cholesterol of 1. Primary prevention of cardiovascular disease with atorvastatin in. The role of statins in diabetes treatment diabetes spectrum.
For the prevention of cardiovascular disease, statins are a firstline treatment. Fenofibrate intervention and event lowering in diabetes. Stroke prediction and stroke prevention with atorvastatin. The objective of this study was to evaluate the safety and tolerability of atorvastatin 10 mg compared with placebo in 2,838 patients with type 2 diabetes and no history of coronary heart disease who were enrolled in the collaborative atorvastatin diabetes study cards and followed for 3. The collaborative atorvastatin diabetes study cards recently established. The study population comprised 2,739 people taking part in the collaborative atorvastatin diabetes study cards who were randomised to.
Baseline characteristics in the collaborative atorvastatin. Cards 2004 treatment comparison n target population entry lipid criteria primary endpoint atorvastatin 10mg vs. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes cards overview 1 a multicenter randomized placebo controlled trial to determine hard outcomes of atorvastatin 10mg vs. Openurl1crossref2pubmed3web of science4 q in patients with type 2 diabetes mellitus, is atorvastatin better than. Atorvastatin, sold under the brand name lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipid levels. Colhoun hm1, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, thomason mj, mackness mi, charltonmenys v, fuller jh. Cards was a doubleblind, randomised, placebocontrolled, multicentre trial of atorvastatin 10 mg daily in the primary prevention of cardiovascular disease in type 2 diabetes 1618. An overview of cards collaborative atorvastatin diabetes.
Abstract background there are few data on the role of lipid lowering in the primary prevention of coronary heart disease chd in diabetic. Colhoun was coprincipal investigator of the collaborative atorvastatin diabetes study cards, a trial of primary prevention with atorvastatin 10 mg daily in almost 3000 patients with type 2 diabetes without high ldlcholesterol. A post hoc analysis of data from the collaborative atorvastatin diabetes study cards, a randomised, placebocontrolled trial of 2,838. Objective diabetesassociated autoantibodies can be detected in adultonset diabetes, even when initially noninsulin requiring, i. The aim of the collaborative atorvastatin diabetes study cards was to assess the effectiveness of 10 mg of atorvastatin daily versus placebo in the primary prevention of cardiovascular disease in patients with type 2 diabetes. Design of the collaborative atorvastatin diabetes study cards. Colhoun hm, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, et al cards investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes. Researchdesignand methodswe used a nested casecontrol design sampling all incident cases of cvd with available plasma and randomly selecting three control subjects, who were free of cvd throughout followup, per case. Ironically, there is a very compelling clinical trial showing the value of one statin, lipitor atorvastatin, in type 2 diabetes the collaborative atorvastatin diabetes study known as cards. Collaborative atorvastatin diabetes study cards 2838 primary prevention patients no ascvd with type 2 diabetes at least 1 other cv risk factor such as smoking, hypertension, retinopathy, or microalbuminuria ldlc levels. Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of. The collaborative atorvastatin diabetes study cards is a multi.
The collaborative atorvastatin diabetes study cards was a doubleblind, randomized, placebocontrolled, multicenter trial of atorvastatin 10 mgday for the primary prevention of cvd in type 2 diabetes. Current clinical practice is based on relatively few randomized, control trials. The aim of the collaborative atorvastatin diabetes. Mar 26, 2002 methods the collaborative atorvastatin diabetes study cards is a multicentre, randomized, placebo. Data from the collaborative atorvastatin diabetes study cards were used colhoun et al. Pdf baseline characteristics in the collaborative atorvastatin. Design of the collaborative atorvastatin diabetes study.
Effect of highdose atorvastatin on renal function in. Atorvastin is sold by pfizer under the trade name lipitor and is a member of the drug class statins. The collaborative atorvastatin diabetes study cards, comparing treatment with atorvastatin lipitor, pfizer inc with placebo in 2800 patients with type 2 diabetes but without overt heart. Besides evaluating global differences, the study also evaluated the effects in three patient risk groups within the trial.
To describe baseline characteristics of patients in the. The collaborative atorvastatin diabetes study cards randomized placebocontrolled trial. Aim to describe baseline characteristics of patients in the collaborative atorvastatin diabetes study cards, a randomized, placebo. Mar 05, 2012 ironically, there is a very compelling clinical trial showing the value of one statin, lipitor atorvastatin, in type 2 diabetes the collaborative atorvastatin diabetes study known as cards. Ofthe collaborative atorvastatin diabetes study cards inthe belgian population marbaix s1,vandenberghe h1,van gaal l2 1p. The collaborative atorvastatin diabetes study cards is a multi centre, randomized, placebocontrolled, doubleblind clinical trial of primary prevention of cardiovascular disease in patients.
984 910 52 1560 453 1209 1524 457 871 1116 1365 611 1630 234 1562 1024 357 1274 738 1357 1614 1140 1549 1057 896 1010 865 1309 794 90 1084 353 1265 13 1294